Price (delayed)
$7.1899
Market cap
$33.13M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$13.76
Enterprise value
$15.73M
Kala is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for diseases of the eye. Kala has applied its AMPPLIFY® mucus-penetrating particle (MPP) Drug Delivery
There are no recent dividends present for KALA.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.